Home / BiomarkerLive / Overview

Overview

BiomarkerLIVE

The role of biomarkers and molecular profiling in cancer diagnosis and treatment continues to expand. In oncology, a biomarker can indicate cancer type, how a cancer will progress if left untreated, what specific treatment may be most effective for a given cancer, and how well treatment is working over time. For five of the most common types of cancer (lung, prostate, colorectal, breast, and skin), there are more than 75 biomarkers used in clinical practice. The sheer number of treatment options across tumor types and the complexity of delivering care makes it difficult for cancer care providers to integrate new therapeutics, like biomarker testing, into their practices.

Barriers to using biomarker testing are common. Respondents to ACCC’s 2018 Trending Now in Cancer Care Survey indicate that insurance coverage, reimbursement, and insufficient protocols are among the issues working against the widespread implementation of biomarker testing in oncology practices.

To help cancer care providers surmount these and other barriers and enhance their knowledge of this rapidly evolving treatment area, ACCC launched the first phase of BiomarkerLIVE in April 2019. Since then, ACCC has worked with clinical experts and industry leaders to develop a common lexicon of biomarker terminology to promote better communication among cancer care teams; establish a resource library of materials relevant to cancer biomarkers and biomarker testing; and host a how-to webinar that explores how cancer programs can use these tools to implement effective biomarker testing protocols for their patients.

Building on the success of BiomarkerLIVE’s launch, Phase 2 will help cancer providers better understand what is needed to facilitate the integration of precision medicine into everyday practice. The objective of this phase is twofold:

  • Support the multidisciplinary cancer care team with the development of the infrastructure and expertise necessary to facilitate the integration of precision medicine into everyday practice.
  • Develop new tools and platforms to disseminate relevant educational resources to the multidisciplinary cancer care team.

There are four key initiatives for this phase of the project:

  • BiomarkerLIVE 101: A live webinar series, podcast series, and newsletter series will focus on building a foundation and baseline education that support the awareness, understanding, and adoption of biomarker testing.
  • BiomarkerLIVE Voice: A summit will focus on developing and communicating strategies for promoting favorable coverage policies of biomarker testing and appropriate reimbursement based on an understanding of the issues unique to this field.
  • BiomarkerLIVE Tx: ACCC will develop and disseminate a Multidisciplinary Process Improvement Toolkit to support care team members with tools to enable better communication and coordination regarding biomarker testing. ACCC will also create a series of Tumor-Specific Process Improvement Toolkits to demonstrate the application of biomarker testing from diagnosis to post-treatment survivorship.
  • BiomarkerLIVE Dx: ACCC will develop a Patient-Centered Resource Kit to support providers in identifying patients who are strong candidates for biomarker testing and giving those patients the resources they need to make informed treatment decisions.
For more information about this project, please contact Janelle Schrag, MPH, Senior Program Manager, ACCC Provider Education.

Upcoming Events

BiomarkerLIVE Webinar Series
Includes a Live Event on 10/19/2020 at 4:00 PM (EDT)

This webinar series covers the foundational elements of biomarker testing and application in cancer care. Topics include biomarker basics, inherited cancers, cost and coverage, laboratory medicine and tumor-specific case examples.
Register

Presentations & Abstracts

 

Our Partners


Fight-CRC-225x80
LBBC-185x80

Clearity-Foundation-211x80

Our Supporters

logo-abbvie-200x80 This project is supported by AbbVie, Lilly Oncology, and Merck & Co., Inc. BMS-330x80 Phase one of this project was supported by Bristol Myers Squibb.